Galera Therapeutics, Inc. (GRTX)
OTCMKTS · Delayed Price · Currency is USD
0.0450
-0.0020 (-4.26%)
Mar 26, 2026, 4:00 PM EST
Galera Therapeutics Company Description
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.
The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC).
It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC).
The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Galera Therapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | J. Sorensen |
Contact Details
Address: 101 Lindenwood Drive Malvern, Pennsylvania 19355 United States | |
| Phone | 610 725 1500 |
| Website | galeratx.com |
Stock Details
| Ticker Symbol | GRTX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US36338D1081 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. J. Mel Sorensen M.D. | Chief Executive Officer, President and Chairman |
| Joel F. Sussman CMA, CPA | Chief Accounting Officer, Secretary and Treasurer |